Chengdu Easton Biopharmaceuticals Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chengdu Easton Biopharmaceuticals Co., Ltd - overview
Established
2009
Location
Chengdu, Sichuan, China
Primary Industry
Pharmaceuticals
About
Established in 2009 and based in Chengdu, China, Chengdu Easton Biopharmaceuticals Co. , Ltd operates as a pharmaceutical company dedicated to providing chemical drugs. It has branch-offices in Shanghai and Xizang. The company has 115 patents, including 106 invention patents.
It also acquired certifications such as US FDA and EU EMA certification. Easton Biopharmaceuticals has 426 R&D employees. In May 2016, Easton Biopharmaceuticals was listed on the New Third Board. In December 2016, the company raised CNY 70 million in venture funding.
In September 2020. Easton Biopharmaceuticals was listed on the Shanghai Stock Exchange Sci-Tech Innovation Board. The company mainly provides preparation products and active pharmaceutical ingredients. The main products include moxifloxacin hydrochloride, fluoxetine maleate, sodium ibandronate injection, and vecuronium bromide for injection.
The preparation products cover the fields of cardiovascular and cerebrovascular diseases, oncology, endocrinology, central nervous system, and other fields. Easton Biopharmaceuticals has industrialized nearly 30 chemical active pharmaceutical products, and more than 10 chemical active pharmaceutical products have been exported to the international market. In 2022, the company's revenue was CNY 1. 17 billion, and its net income was CNY 246.
52 million.
Current Investors
LYFE Capital, CreditEase Fintech Investment Fund, CITIC Goldstone Fund Management
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Cardiology, Pharmaceutical Research & Development, Specialty Pharmaceuticals, Medicinal Chemicals & Botanicals
Website
www.eastonpharma.cn
Company Stage
Mature
Total Amount Raised
Subscriber access only
Chengdu Easton Biopharmaceuticals Co., Ltd - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 476,337,981.8 | 768,758,600.6 | 947,235,160.4 | 921,479,709.5 | 1,022,935,588 | - | - | - |
| % Revenue Growth (YoY) | - | 61.4% | 23.2% | (2.7%) | 11.0% | - | - | - |
| EBITDA (USD) | 98,346,100 | 173,765,000 | 143,863,400 | 229,611,311.2 | 276,758,204.9 | - | - | - |
| Operating Income (USD) | 74,267,922.7 | 149,135,989.1 | 114,732,604 | 195,675,596.3 | 244,153,275 | - | - | - |
| Operating Margin | 15.6% | 19.4% | 12.1% | 21.2% | 23.9% | - | - | - |
| % EBITDA Margin | 20.6% | 22.6% | 15.2% | 24.9% | 27.1% | - | - | - |
| NET Income (USD) | 64,365,623.7 | 135,020,129.3 | 108,611,577.5 | 178,161,834.5 | 232,427,615 | - | - | - |
| % Net Margin | 13.5% | 17.6% | 11.5% | 19.3% | 22.7% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.